|
Year
|
Title
|
Authors
|
Publication
|
|
2022
|
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.
|
Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen D, Anderson L, Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee C, Mian H, Nathan S, Savani B, Kumar S, Shah N, D'Souza A
|
Blood Adv
|
|
2022
|
Updated trends in hematopoietic cell transplantation in the United States with an additional focus on adolescent and young adult transplantation activity and outcomes.
|
Phelan R, Chen M, Bupp C, Bolon Y-T, Broglie L, Brunner-Grady J, Burns LJ, Chhabra S, Christianson D, Cusatis R, Devine SM, D'Souza A, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini M, Pérez WS, Riches M, Rizzo D, Saber W, Spellman SR, Stefanski HE, Steinert P, Weisdorf D, Horowitz M, Auletta JJ, Shaw BE, Arora M
|
Transplant Cell Ther
|
|
2022
|
Race and survival in unrelated hematopoietic-cell transplantation.
|
Morishima Y, Morishima S, Stevenson P, Kodera Y, Horowitz M, McKallor C, Malkki M, Spellman SR, Gooley T, Petersdorf EW
|
Transplant Cell Ther
|
|
2022
|
Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis BMT CTN 1101Open for Accrual June 2012Open for Accrual June 2012
|
Brunstein CG, O'Donnell P, Logan B, Dawson P, Costa L, Cutler C, Craig M, Hogan W, Horowitz M, Horwitz ME, Karanes C, Magenau JM, Malone A, McCarty J, McGuirk JP, Morris LE, Rezvani AR, Salit R, Vasu S, Eapen M, Fuchs EJ
|
Transplant Cell Ther
|
|
2022
|
Age is no barrier for adults undergoing HCT for AML in CR1: Contemporary CIBMTR analysis.
|
Maakaron J, Zhang M-J, Chen K, Abhyankar S, Bhatt VR, Chhabra S, El Jurdi N, Farag SS, He F, Juckett M, de Lima, Majhail N, van der Poel M, Saad A, Savani B, Ustun C, Waller EK, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D
|
Bone Marrow Transplant
|
|
2022
|
A calibrated Bayesian method for the stratified proportional hazards model with missing covariates.
|
Kim S, Kim J-K, Ahn KW
|
Lifetime Data Anal 28(2):169-193
|
|
2022
|
Competing risks regression models with covariates-adjusted censoring weight under the generalized case-cohort design.
|
Xu Y, Kim S, Zhang M-J, Couper D, Ahn KW
|
Lifetime Data Anal 28(2):241-262
|
|
2022
|
Outcomes of allogeneic hematopoietic cell transplantation in T cell prolymphocytic leukemia: A contemporary analysis from the Center for International Blood and Marrow Transplant Research.
|
Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W
|
Transplant Cell Ther 28(4):187.e1-187.e10
|
|
2022
|
Correction to: A SAS macro for estimating direct adjusted survival functions for time-to-event data with or without left truncation.
|
Hu Z-H, Wang H-L, Gale RP, Zhang M-J
|
Bone Marrow Transplant 57(4):693
|
|
2022
|
Increasing access to hematopoietic cell transplantation in Latin America: results of the 2018 LABMT activity survey and trends since 2012.
|
Correa C, Gonzalez-Ramella O, Baldomero H, Basquiera AL, Baena R, Arcuri L, Puga B, Rosales C, Chávez M, Hernández C, Maldonado B, Gómez-De León A, Mendoza N, Frutos C, Aranda L, Díaz L, Hernández M, Seber A, Karduss A, Jaimovich G, Martínez-Rolon J, Bonfim C, Greinix H, Koh MBC, Aljurf M, Iida M, Saber W, Niederwieser D, Atsuta Y, Galeano S
|
Bone Marrow Transplant
|
|
2022
|
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia.
|
Baccarani M, Bonifazi F, Soverini S, Castagnetti F, Guliotta G, Saber W, Estrada-Merly N, Rosti G, Gale RP
|
Leukemia
|
|
2022
|
Non-infectious pulmonary toxicity after allogeneic hematopoietic cell transplantation.
|
Patel SS, Ahn KW, Khanal M, Bupp C, Allbee-Johnson M, Majhail NS, Hamilton BK, Rotz SJ, Hashem H, Beitinjaneh A, Lazarus HM, Krem MM, Prestidge T, Bhatt NS, Sharma A, Gadalla SM, Murthy HS, Broglie L, Nishihori T, Freytes CO, Hildebrandt GC, Gergis U, Seo S, Wirk B, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S
|
Transplant Cell Ther
|
|
2022
|
Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.
|
Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang M-J, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn J-Y, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D
|
Bone Marrow Transplant
|
|
2022
|
Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?
|
Abou-Ismail MY, Fraser R, Allbee-Johnson M, Metheny III L, Ravi G, Ahn KW, Bhatt NS, Lazarus HM, de Lima M, El Jurdy N, Hematti P, Beitinjaneh AM, Nishihori T, Badawy SM, Sharma A, Pasquini MC, Savani BN, Sorror ML, Stadtmauer E, Chhabra S
|
Br J Haematol
|
|
2022
|
Long-term survival after hematopoietic cell transplant for sickle cell disease compared to the United States population.
|
StMartin A, Hebert KM, Serret-Larmande A, Jouhet V, Hughes E, Stedman J, DeSain T, Pillion D, Lyons JC, Steinert P, Avillach P, Eapen M
|
Transplant Cell Ther
|
|
2022
|
HLA-DQ heterodimers in hematopoietic-cell transplantation.
|
Petersdorf EW, Bengtsson M, Horowitz MM, McKallor C, Spellman SR, Spierings E, Gooley TA, Stevenson PA
|
Blood
|
|
2022
|
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide.
|
Fuchs EJ, McCurdy SR, Solomon SR, Wang T, Herr MR, Modi D, Grunwald MR, Nishihori T, Kuxhausen M, Fingerson S, McKallor C, Bashey A, Kasamon YL, Bolon Y-T, Saad A, McGuirk J, Paczesny S, Gadalla SM, Marsh SGE, Shaw BE, Spellman SR, Lee SJ, Petersdorf EW
|
Blood 139(10):1452-1468
|
|
2022
|
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
|
Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi PN, Beitinjaneh A, Reagan P, Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M
|
Blood 139(9):1330-1339
|
|
2022
|
Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors.
|
Guru Murthy GS, Kim S, Hu Z-H, Estrada-Merly N, Abid MB, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bredeson C, Cahn J-Y, Cerny J, Diaz Perez MA, Farhadfar N, Gale RP, Ganguly S, Gergis U, Hildebrandt GC, Grunwald MR, Hashmi S, Hossain NM, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Hamilton BK, Lazarus HM, Liesveld J, Litzow M, Marks DI, Murthy HS, Nathan S, Nazha A, Nishihori T, Patel SS, Pawarode A, Rizzieri D, Savani B, Seo S, Solh M, Ustun C, van der Poel M, Verdonck LF, Vij R, Wirk B, Oran B, Nakamura R, Scott B, Saber W
|
JAMA Oncol 8(3):404-411
|
|
2022
|
Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.
|
Marsh RA, Hebert K, Kim S, Dvorak CC, Aquino VM, Baker KS, Chellapandian D, Dávila Saldaña B, Duncan CN, Eckrich MJ, Georges GE, Olson TS, Pulsipher MA, Shenoy S, Stenger E, Lugt MV, Yu LC, Gennery AR, Eapen M
|
J Allergy Clin Immunol 149(3):1097-1104.e2
|
|
2022
|
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.
|
Stewart MD, McCall B, Pasquini M, Yang AS, Britten CD, Chuk M, DeClaro RA, George B, Gormley N, Horowitz MM, Kowack E, McCoy C, Morrow PK, Okoye E, Ricafort R, Rossi J, Sharon E, Theoret M, Vegni F, Yu T, Allen J
|
Cytotherapy
|
|
2022
|
Two-sample survival probability curves: A graphical approach for the analysis of time to event data in clinical trials
|
CP Sandra, L Chap, L Xianghua
|
Contemp Clin Trials
|
|
2022
|
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).
|
Dispenzieri A, Krishnan A, Arendt B, Blackwell B, Wallace PK, Dasari S, Vogl DT, Efebera Y, Fei M, Geller N, Giralt S, Hahn T, Howard A, Kohlhagen M, Landau H, Hari P, Pasquini MC, Qazilbash MH, McCarthy P, Shah N, Vesole D, Stadtmauer E, Murray D
|
Blood Cancer J 12(2):27
|
|
2022
|
Outcome of allogeneic transplantation for mature T-cell lymphomas: Impact of donor source and disease characteristics.
|
Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, Chen Y, Boumendil A, Zain J, Castagna L, Cashen AF, Blaise D, Shadman M, Pastano R, Khimani F, Arat M, Dietrich S, Schmitz N, Glass B, Kharfan-Dabaja MA, Corradini P, Sauter CS, Montoto S, Kwon M, Herrera AF, Dreger P
|
Blood Adv 6(3):920-930
|
|
2022
|
Impact of induction therapy with VRD versus VCD on outcomes in patients with multiple myeloma in partial response or better undergoing upfront autologous stem cell transplantation.
|
Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD Jr, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A
|
Transplant Cell Ther 8(2):e1-83.e9
|
|
2022
|
Autologous hematopoietic cell transplantation in diffuse large B-cell limphoma after 3 or more lines of prior therapy: evidence of durable benefit.
|
Mei M, Hamadani M, Ahn KW, Chen Y, Kharfan-Dabaja MA, Sauter C, Herrera AF
|
Haematologica
|
|
2022
|
Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
|
Savani M, Ahn KW, Chen Y, Ahmed S, Cashen AF, Shadman M, Modi D, Khimani F, Cutler CS, Zain J, Brammer JE, Rezvani AR, Fenske TS, Sauter CS, Kharfan-Dabaja MA, Herrera AF, Hamadani M
|
Br J Haematol
|
|
2022
|
Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies.
|
Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA
|
J Clin Oncol 40(4):356-368
|
|
2022
|
Adding centralized electronic patient-reported outcome data collection to an established international clinical outcomes registry.
|
Cusatis R, Flynn KE, Vasu S, Pidala J, Muffly L, Uberti J, Tamari R, Mattila D, Mussetter A, Bruzauskas R, Chen M, Leckrone E, Myers J, Mau L-W, Rizzo JD, Saber W, Horowitz M, Lee SJ, Burns LJ, Shaw B
|
Transplant Cell Ther 28(2):112.e1-112.e9
|
|
2022
|
A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients.
|
Tan CR, Estrada-Merly N, Landau H, Lekakis L, Banerjee R, Mian H, Usmani SZ, Hanbali A, Lazarus HM, Kyle RA, Dholaria B, Bal S, Strouse C, Murthy HS, Wirk B, Nishihori T, Kumar S, Shah N, Qazilbash M, D'Souza A
|
Bone Marrow Transplant 57(2):295-298
|
|
2022
|
Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD.
|
Meyers G, Hamadani M, Martens M, Ali H, Choe H, Dawson P, Harris AC, van Hooren E, Klaassen W, Leifer E, MacMillan ML, van Oosterhout Y, Perez L, Pusic I, Vo P, Levine JE
|
Bone Marrow Transplant 57(2):302-303
|
|
2022
|
Number of HLA-mismatched eplets is not associated with major outcomes in haploidentical transplantation with post-transplantation cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study.
|
Zou J, Wang T, He M, Bolon YT, Gadalla SM, Marsh SGE, Kuxhausen M, Gale RP, Sharma A, Assal A, Prestidge T, Aljurf M, Cerny J, Paczesny S, Spellman SR, Lee SJ, Ciurea SO
|
Transplant Cell Ther 28(2):107.e1-107.e8
|
|
2022
|
Umbilical cord blood or HLA-haploidentical transplantation: Real-world outcomes versus randomized trial outcomes.
|
O'Donnell PV, Brunstein CG, Fuchs EJ, Zhang M-J, Allbee-Johnson M, Antin JH, Leifer ES, Elmariah H, Grunwald MR, Hashmi H, Horowitz MM, Magenau JM, Majhail N, Milano F, Morris LE, Rezvani AR, McGuirk JP, Jones RJ, Eapen M
|
Transplant Cell Ther 28(2):109.e1-109.e8
|
|
2022
|
Outcomes in hematopoietic stem cell transplantation for congenital amegakaryocytic thrombocytopenia.
|
Cancio M, Hebert K, Kim S, Aljurf M, Olson T, Anderson E, Burroughs L, Vatsayan A, Myers K, Hashem H, Hanna R, Horn B, Prestidge T, Boelens JJ, Boulad F, Eapen M
|
Transplant Cell Ther 28(2):101.e1-101.e6
|
|
2022
|
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: A noncomparative cohort analysis.
|
Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, Lazaryan A, Bhatt VR, Daly A, Lulla P, Ciurea S, Gauthier J, Agrawal V, Grover NS, Lekakis L, Modi D, Dahi PB, Herr MM, Johnson PC, Hashmi H, Hematti P, Locke FL
|
Blood Adv 6(2):486-494
|
|
2022
|
Assessment of HLA-B genetic variation with an HLA-B leader tool and implications in clinical transplantation.
|
Sajulga R, Bolon Y-T, Maiers MJ, Petersdorf EW
|
Blood Adv 6(1):270-280
|
|
2022
|
Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.
|
Wieduwilt MJ, Metheny L, Zhang MJ, Wang H-L, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao NJ, Rizzieri D, Gale RP, Gadalla SM, Cairo MS, Mussetti A, Gore SD, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson CN, Diaz Perez MA, Cassaday R, Savani BN, Ballen KK, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel M, van der Poel MWM, Grunwald MR, Liesveld JL, Kamble RT, McGuirk JP, Munker R, Cahn J-Y, Lee JW, Freytes CO, Krem M, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringden O, Friend BD, Cerny J, Choe HK, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, De Lima M, Litzow MR, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W
|
Blood Adv 6(1):339-357
|
|
2022
|
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.
|
Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang M-J, Bo-Subait K, Sanchez J, Wang H-L, Aljurf M, Assal A, Bacher VU, Badawy SM, Bejanyan N, Bhatt VR, Bredeson CN, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus H, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson R, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan C, Sandmaier B, Litzow M, Kebriaei P, Weisdorf D, Zhang Y, Tallman MS, Saber W
|
Blood Adv 6(3):828-847
|
|
2022
|
Genetic associations with immune-mediated outcomes after allogeneic hematopoietic cell transplantation.
|
Martin PJ, Levine D, Storer BE, Sather CL, Spellman SR, Hansen JA
|
Blood Adv
|
|
2022
|
Decrease post-transplant relapse using donor-derived expanded NK-cells.
|
Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani A, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE
|
Leukemia 36(1):155-164
|
|
2022
|
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.
|
Pasvolsky O, Yeshurun M, Fraser R, Estrada-Merly N, Rozovski U, Shargian-Alon L, Assal A, Banerjee R, Bumma N, Gale RP, Hagen P, Holmberg L, Hossain NM, Lazarus HM, Lee C, Mian H, Miller KC, Nathan S, Nagler A, Nishihori T, Parrondo RD, Patel S, Schroeder MA, Usmani SZ, Wang T, Wirk B, Kumar S, Shah N, Qazilbash MH, D'Souza A
|
Bone Marrow Transplant 57(1):31-37
|
|
2022
|
New indications and platforms for CAR-T therapy in lymphomas beyond DLBCL.
|
Iqbal M, Savani BN, Hamadani M
|
EJHaem 3(Suppl 1):11-23
|
|
2022
|
Post-transplantation cyclophosphamide is associated with an increase in non-cytomegalovirus herpesvirus infections in patients with acute leukemia and myelodysplastic syndrome.
|
Singh A, Dandoy CE, Chen M, Kim S, Mulroney CM, Kharfan-Dabaja MA, Ganguly S, Maziarz RT, Kanakry CG, Kanakry JA, Patel SS, Hill JA, De Oliveir S, Taplitz R, Hematti P, Lazarus HM, Abid MB, Goldsmith SR, Romee R, Komanduri KV, Badawy SM, Friend BD, Beitinjaneh A, Politikos I, Perales M-A, Riches M
|
Transplant Cell Ther 2(1):48.e1-48.e10
|
|
2022
|
Chronic graft-versus-host disease, nonrelapse mortality, and disease relapse in older versus younger adults undergoing matched allogeneic peripheral blood hematopoietic cell transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
|
Bhatt VR, Wang T, Chen K, Kitko CL, MacMillan ML, Pidala JA, Malki MM, Badawy SM, Beitinjaneh A, Ganguly S, Hamilton B, Hildebrandt GC, Lekakis LJ, Liu H, Maziarz RT, Modi D, Murthy HS, Preussler JM, Sharma A, Spellman SR, Arora M, Lee SJ
|
Transplant Cell Ther 28(1):34-42
|
|
2022
|
Case-cohort design in hematopoietic cell transplant studies.
|
Cai J, Kim S
|
Bone Marrow Transplant 57(1):1-5
|
|
2022
|
A SAS macro for estimating direct adjusted survival functions for time-to-event data with or without left truncation.
|
Hu Z-H, Wang H-L, Gale RP, Zhang M-J
|
Bone Marrow Transplant 57(1):6-10
|
